Literature DB >> 29936017

Developmental trajectories of executive functions in young males with fragile X syndrome.

Stephen R Hooper1, Deborah Hatton2, John Sideris3, Kelly Sullivan4, Peter A Ornstein5, Donald B Bailey6.   

Abstract

BACKGROUND: Executive functions (EF) have been identified as impaired in FXS, but few studies have examined their developmental trajectories. AIMS: The primary aim of this longitudinal study was to examine the development of EF in young males with FXS compared to Mental Age (MA)-matched controls. METHODS AND PROCEDURES: The sample comprised 56 boys with FXS (ages 7-13 years), and 48 MA-matched typical boys (ages 4-8 years). EF tasks included measures of inhibitory control, working memory, cognitive flexibility/set-shifting, problem solving/planning, and processing speed. Tasks were administered at three time points over five-years. OUTCOMES AND
RESULTS: The MA-Matched Typical boys significantly outperformed the FXS boys on all EF tasks, with the FXS Group showing a pattern of slow, but positive growth on most EF tasks. For working memory tasks, significant interactions were noted between MA and autism symptom severity, and MA and medication status. The probability of task completion increased with higher MA. CONCLUSIONS AND IMPLICATIONS: These findings contribute to our understanding of the development of EF in this population. They also lay the foundation for use of EF tasks in treatment efforts, particularly with respect to documenting improvements and practice effects, and in understanding associations with targeted developmental outcomes.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive development in FXS; Executive function development; Executive functions; Fragile X syndrome (FXS); Intellectual disabilities

Mesh:

Year:  2018        PMID: 29936017     DOI: 10.1016/j.ridd.2018.05.014

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  4 in total

1.  Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.

Authors:  Jennifer L Bruno; Sm Hadi Hosseini; Amy A Lightbody; Mai K Manchanda; Allan L Reiss
Journal:  J Psychopharmacol       Date:  2019-07-02       Impact factor: 4.153

2.  Rates and Predictors of Co-occurring Autism Spectrum Disorder in Boys with Fragile X Syndrome.

Authors:  Eileen Haebig; Audra Sterling; Andrea Barton-Hulsey; Laura Friedman
Journal:  Autism Dev Lang Impair       Date:  2020-02-12

3.  Sustained correction of associative learning deficits after brief, early treatment in a rat model of Fragile X Syndrome.

Authors:  Antonis Asiminas; Adam D Jackson; Susana R Louros; Sally M Till; Teresa Spano; Owen Dando; Mark F Bear; Sumantra Chattarji; Giles E Hardingham; Emily K Osterweil; David J A Wyllie; Emma R Wood; Peter C Kind
Journal:  Sci Transl Med       Date:  2019-05-29       Impact factor: 17.956

4.  Polysomnographic Findings in Fragile X Syndrome Children with EEG Abnormalities.

Authors:  Marco Carotenuto; Michele Roccella; Francesco Pisani; Sara Matricardi; Alberto Verrotti; Giovanni Farello; Francesca Felicia Operto; Ilaria Bitetti; Francesco Precenzano; Giovanni Messina; Maria Ruberto; Cristiana Ciunfrini; Mariagrazia Riccardi; Eugenio Merolla; Grazia Maria Giovanna Pastorino; Anna Nunzia Polito; Rosa Marotta
Journal:  Behav Neurol       Date:  2019-12-03       Impact factor: 3.342

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.